SAN FRANCISCO, CA—(Marketwired – March 08, 2018) – Dance Biopharm Holdings Inc. (“Dance”), a privately–held biotechnology company focused on the development of Dance 501, a proprietary 'soft–mist' inhaled insulin product to treat diabetes, is pleased to announce the appointment of Benjamin Wolin to its board of directors. Wolin was co–founder and CEO of Everyday Health (NYSE: EVDY), the leading digital marketing and communication platform for consumers, doctors and healthcare companies, until it was acquired by Ziff Davis, LLC in 2016 for ~$465M.
“Adding Ben to the Board of Directors is an important step forward for Dance. Ben is a proven executive who has deep experience in digital health, pharma marketing and commercialization as well as IPO and public board successes,” said John Patton, Chairman and Chief Executive Officer of Dance Biopharm. “His background and enthusiasm for our opportunity will be invaluable as we continue to develop our transformative product — position it for commercial success — and build a leading franchise in the diabetes category.”
“John and the rest of the Dance team have created an amazing opportunity to both build a significant business and help millions of patients manage their diabetes without the pain and frustration of daily injections. I am thrilled to join the Board of Directors in order to help Dance succeed and fulfill its fantastic mission,” stated Wolin.
Wolin is currently Chairman of Diplomat Specialty Pharmacy (NYSE: DPLO), the nation's largest independent specialty pharmacy, and serves as an advisor and board member to a variety of other leading technology and healthcare organizations. Ben is a graduate of Bowdoin College and started his career managing digital media for PBS, Tribune Interactive, Warner Bros. and A&E.
Dance was introduced to Ben Wolin through engagement with Jodie Emery of Ignite Search Partners.
About Dance Biopharm
Dance Biopharm is a privately–held company based in the San Francisco Bay Area focused on the clinical development of inhaled insulin products to treat diabetes patients worldwide. The company began operations in 2010, founded by Dr. John Patton, who has over 25 years of experience developing inhaled insulin and other inhaled therapies. For more information, please visit http://dancebiopharm.com.
About Dance 501, an Inhaled Insulin Product
Dance 501 consists of a high purity liquid formulation of recombinant human insulin stored in a dispenser for administration with a small handheld electronic inhaler. The electronic inhaler utilizes a patented vibrating mesh technology, designed to produce consistently sized particles of liquid insulin in the form of a soft mist, allowing the efficient and consistent delivery of insulin into the lungs in a few breaths. Dance 501 has not yet been approved by any regulatory authority.
All statements other than statements of historical fact included in this press release are forward–looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. We have based these forward–looking statements upon information available to management of Dance as of the date of this release and management's expectations and projections about certain future events. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward–looking statements. Such statements may involve risks and uncertainties, including but not limited to those relating to our limited operating history, our ability to successfully develop Dance 501, the cost and uncertainty of obtaining regulatory approvals, changes in the competitive or regulatory landscape and our ability to develop and commercialize a Connected Health Pulmonary drug delivery system.